Literature DB >> 20630766

The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.

Maris A Cinelli1, Andrew E Morrell, Thomas S Dexheimer, Keli Agama, Surbhi Agrawal, Yves Pommier, Mark Cushman.   

Abstract

n class="Chemical">Aromathecins are inhibitors of human topoisomerase I (Top1). These compounds are composites of several heteroaromatic systems, namely the camptothecins and indenoisoquinolines, and they possess notable Top1 inhibition and cytotoxicity when substituted at position 14. The SAR of these compounds overlaps with indenoisoquinolines, suggesting that they may intercalate into the Top1-DNA complex similarly. Nonetheless, the proposed binding mode for aromathecins is purely hypothetical, as an X-ray structure is unavailable. In the present communication, we have synthesized eight novel series of A-ring-substituted (positions 1-3) aromathecins, through a simple, modular route, as part of a comprehensive SAR study. Certain groups (such as 2,3-ethylenedioxy) moderately improve Top1 inhibition, and, often, antiproliferative activity, whereas other groups (2,3-dimethoxy and 3-substituents) attenuate bioactivity. Strikingly, these trends are very similar to those previously observed for the A-ring of camptothecins, and this considerable SAR overlap lends further support (in the absence of crystallographic data) to the hypothesis that aromathecins bind in the Top1 cleavage complex as interfacial inhibitors in a 'camptothecin-like' pose. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630766      PMCID: PMC2911012          DOI: 10.1016/j.bmc.2010.06.040

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  53 in total

1.  Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.

Authors:  Andrew Morrell; Michael Placzek; Seth Parmley; Brian Grella; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2007-08-04       Impact factor: 7.446

2.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

3.  DNA cleavage assay for the identification of topoisomerase I inhibitors.

Authors:  Thomas S Dexheimer; Yves Pommier
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

4.  Concise synthesis of 22-hydroxyacuminatine, cytotoxic camptothecinoid from Camptotheca acuminata, by pyridone benzannulation.

Authors:  Matej Babjak; Alice Kanazawa; Regan J Anderson; Andrew E Greene
Journal:  Org Biomol Chem       Date:  2005-12-14       Impact factor: 3.876

5.  Chimmitecan, a novel 9-substituted camptothecin, with improved anticancer pharmacologic profiles in vitro and in vivo.

Authors:  Min Huang; Heyong Gao; Yi Chen; Hong Zhu; Yujun Cai; Xiongwen Zhang; Zehong Miao; Hualiang Jiang; Jian Zhang; Hongwu Shen; Liping Lin; Wei Lu; Jian Ding
Journal:  Clin Cancer Res       Date:  2007-02-07       Impact factor: 12.531

Review 6.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.

Authors:  Beverly A Teicher
Journal:  Biochem Pharmacol       Date:  2007-10-22       Impact factor: 5.858

7.  Synthesis and cytotoxic activity of new 9-substituted camptothecins.

Authors:  Sabrina Dallavalle; Daniela Granza Rocchetta; Loana Musso; Lucio Merlini; Gabriella Morini; Sergio Penco; Stella Tinelli; Giovanni Luca Beretta; Franco Zunino
Journal:  Bioorg Med Chem Lett       Date:  2008-04-10       Impact factor: 2.823

8.  Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.

Authors:  Smitha Antony; Keli K Agama; Ze-Hong Miao; Kazutaka Takagi; Mollie H Wright; Ana I Robles; Lyuba Varticovski; Muthukaman Nagarajan; Andrew Morrell; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

9.  Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Authors:  Thomas D Pfister; William C Reinhold; Keli Agama; Shalu Gupta; Sonny A Khin; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2009-07-07       Impact factor: 6.261

10.  A domino N-amidoacylation/aldol-type condensation approach to the synthesis of the topo-I inhibitor Rosettacin and derivatives.

Authors:  Frédéric Pin; Sébastien Comesse; Morgane Sanselme; Adam Daïch
Journal:  J Org Chem       Date:  2008-02-07       Impact factor: 4.354

View more
  7 in total

1.  Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models.

Authors:  Mohammed Hussaini Bohari; Hemant Kumar Srivastava; Garikapati Narahari Sastry
Journal:  Org Med Chem Lett       Date:  2011-07-18

2.  Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.

Authors:  Katherine E Peterson; Maris A Cinelli; Andrew E Morrell; Akhil Mehta; Thomas S Dexheimer; Keli Agama; Smitha Antony; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2011-06-28       Impact factor: 7.446

3.  Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.

Authors:  Maris A Cinelli; P V Narasimha Reddy; Peng-Cheng Lv; Jian-Hua Liang; Lian Chen; Keli Agama; Yves Pommier; Richard B van Breemen; Mark Cushman
Journal:  J Med Chem       Date:  2012-12-07       Impact factor: 7.446

Review 4.  Imidazoles as potential anticancer agents.

Authors:  Imran Ali; Mohammad Nadeem Lone; Haasan Y Aboul-Enein
Journal:  Medchemcomm       Date:  2017-04-13       Impact factor: 3.597

5.  Activity of Aromathecins against African Trypanosomes.

Authors:  Nathaniel P Nenortas; Maris A Cinelli; Andrew E Morrell; Mark Cushman; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

6.  Design, Synthesis and Cytotoxicity Evaluation of New 2-Aryl-5, 6-Dihydropyrrolo[2, 1-a]Isoquinoline Derivatives as Topoisomerase Inhibitors.

Authors:  Samaneh Kakhki; Sorayya Shahosseini; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

7.  Antiparasitic effect of synthetic aromathecins on Leishmania infantum.

Authors:  Rosa M Reguera; Raquel Álvarez-Velilla; Bárbara Domínguez-Asenjo; Camino Gutiérrez-Corbo; Rafael Balaña-Fouce; Mark Cushman; Yolanda Pérez-Pertejo
Journal:  BMC Vet Res       Date:  2019-11-09       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.